Acta Neurochirurgica

, Volume 152, Issue 1, pp 1–17 | Cite as

Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics

  • Erzsébet Kövesdi
  • János Lückl
  • Péter Bukovics
  • Orsolya Farkas
  • József Pál
  • Endre Czeiter
  • Dóra Szellár
  • Tamás Dóczi
  • Sámuel Komoly
  • András Büki
Review Article



This review summarizes protein biomarkers in mild and severe traumatic brain injury in adults and children and presents a strategy for conducting rationally designed clinical studies on biomarkers in head trauma.


We performed an electronic search of the National Library of Medicine’s MEDLINE and Biomedical Library of University of Pennsylvania database in March 2008 using a search heading of traumatic head injury and protein biomarkers. The search was focused especially on protein degradation products (spectrin breakdown product, c-tau, amyloid-β1–42) in the last 10 years, but recent data on “classical” markers (S-100B, neuron-specific enolase, etc.) were also examined.


We identified 85 articles focusing on clinical use of biomarkers; 58 articles were prospective cohort studies with injury and/or outcome assessment.


We conclude that only S-100B in severe traumatic brain injury has consistently demonstrated the ability to predict injury and outcome in adults. The number of studies with protein degradation products is insufficient especially in the pediatric care. Cohort studies with well-defined end points and further neuroproteomic search for biomarkers in mild injury should be triggered. After critically reviewing the study designs, we found that large homogenous patient populations, consistent injury, and outcome measures prospectively determined cutoff values, and a combined use of different predictors should be considered in future studies.


Review Mild Severe Pediatric Traumatic brain injury Biomarkers Outcome 


  1. 1.
    Abrahamson EE, Ikonomovic MD, Ciallella JR, Hope CE, Paljug WR, Isanski BA, Flood DG, Clark RS, Dekosky ST (2006) Caspase inhibition therapy abolishes brain trauma-induced increases in Abeta peptide: implications for clinical outcome. Exp Neurol 197:437–450PubMedGoogle Scholar
  2. 2.
    Anderson RE, Hansson LO, Nilsson O, jlai-Merzoug R, Settergren G (2001) High serum S100B levels for trauma patients without head injuries. Neurosurgery 48:1255–1258PubMedGoogle Scholar
  3. 3.
    Aono M, Bennett ER, Kim KS, Lynch JR, Myers J, Pearlstein RD, Warner DS, Laskowitz DT (2003) Protective effect of apolipoprotein E-mimetic peptides on N-methyl-d-aspartate excitotoxicity in primary rat neuronal–glial cell cultures. Neuroscience 116:437–445PubMedGoogle Scholar
  4. 4.
    Balestreri M, Czosnyka M, Chatfield DA, Steiner LA, Schmidt EA, Smielewski P, Matta B, Pickard JD (2004) Predictive value of Glasgow Coma Scale after brain trauma: change in trend over the past ten years. J Neurol Neurosurg Psychiatry 75:161–162PubMedGoogle Scholar
  5. 5.
    Bandyopadhyay S, Hennes H, Gorelick MH, Wells RG, Walsh-Kelly CM (2005) Serum neuron-specific enolase as a predictor of short-term outcome in children with closed traumatic brain injury. Acad Emerg Med 12:732–738PubMedGoogle Scholar
  6. 6.
    Barzo P, Marmarou A, Fatouros P, Corwin F, Dunbar JG (1997) Acute blood–brain barrier changes in experimental closed head injury as measured by MRI and Gd-DTPA. Acta Neurochir Suppl 70:243–246PubMedGoogle Scholar
  7. 7.
    Baydas G, Nedzvetskii VS, Nerush PA, Kirichenko SV, Yoldas T (2003) Altered expression of NCAM in hippocampus and cortex may underlie memory and learning deficits in rats with streptozotocin-induced diabetes mellitus. Life Sci 73:1907–1916PubMedGoogle Scholar
  8. 8.
    Bazarian JJ, Beck C, Blyth B, von AN, Hasselblatt M (2006) Impact of creatine kinase correction on the predictive value of S-100B after mild traumatic brain injury. Restor Neurol Neurosci 24:163–172PubMedGoogle Scholar
  9. 9.
    Beaudeux J, Dequen L, Foglietti M (1999) Pathophysiologic aspects of S-100beta protein: a new biological marker of brain pathology. Ann Biol Clin (Paris) 57:261–272Google Scholar
  10. 10.
    Beems T, Simons KS, Van Geel WJ, De Reus HP, Vos PE, Verbeek MM (2003) Serum- and CSF-concentrations of brain specific proteins in hydrocephalus. Acta Neurochir (Wien) 145:37–43Google Scholar
  11. 11.
    Beers SR, Berger RP, Adelson PD (2007) Neurocognitive outcome and serum biomarkers in inflicted versus non-inflicted traumatic brain injury in young children. J Neurotrauma 24:97–105PubMedGoogle Scholar
  12. 12.
    Berg J, Tagliaferri F, Servadei F (2005) Cost of trauma in Europe. Eur J Neurol 12(Suppl 1):85–90PubMedGoogle Scholar
  13. 13.
    Berger RP (2006) The use of serum biomarkers to predict outcome after traumatic brain injury in adults and children. J Head Trauma Rehabil 21:315–333PubMedGoogle Scholar
  14. 14.
    Berger RP, Adelson PD, Pierce MC, Dulani T, Cassidy LD, Kochanek PM (2005) Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg 103:61–68PubMedGoogle Scholar
  15. 15.
    Berger RP, Beers SR, Richichi R, Wiesman D, Adelson PD (2007) Serum biomarker concentrations and outcome after pediatric traumatic brain injury. J Neurotrauma 24:1793–1801PubMedGoogle Scholar
  16. 16.
    Berger RP, Dulani T, Adelson PD, Leventhal JM, Richichi R, Kochanek PM (2006) Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers: a possible screening tool. Pediatrics 117:325–332PubMedGoogle Scholar
  17. 17.
    Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Clark RS, Ruppel RA, Kochanek PM (2002) Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatrics 109:E31PubMedGoogle Scholar
  18. 18.
    Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Kochanek PM (2002) Serum S100B concentrations are increased after closed head injury in children: a preliminary study. J Neurotrauma 19:1405–1409PubMedGoogle Scholar
  19. 19.
    Biberthaler P, Linsenmeier U, Pfeifer KJ, Kroetz M, Mussack T, Kanz KG, Hoecherl EF, Jonas F, Marzi I (2006) Serum S-100B concentration provides additional information fot the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock 25:446–453PubMedGoogle Scholar
  20. 20.
    Binder LI, Frankfurter A, Rebhun LI (1985) The distribution of tau in the mammalian central nervous system. J Cell Biol 101:1371–1378PubMedGoogle Scholar
  21. 21.
    Blasko I, Beer R, Bigl M, Apelt J, Franz G, Rudzki D, Ransmayr G, Kampfl A, Schliebs R (2004) Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1). J Neural Transm 111:523–536PubMedGoogle Scholar
  22. 22.
    Blennow K, Hesse C, Fredman P (1994) Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. Neuroreport 5:2534–2536PubMedGoogle Scholar
  23. 23.
    Blennow K, Nellgard B (2004) Amyloid beta 1–42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 62:159–160PubMedGoogle Scholar
  24. 24.
    Blomquist S, Johnsson P, Luhrs C, Malmkvist G, Solem JO, Alling C, Stahl E (1997) The appearance of S-100 protein in serum during and immediately after cardiopulmonary bypass surgery: a possible marker for cerebral injury. J Cardiothorac Vasc Anesth 11:699–703PubMedGoogle Scholar
  25. 25.
    Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons (2007) Guidelines for the management of severe traumatic brain injury. J Neurotrauma 24(Suppl):1–106Google Scholar
  26. 26.
    Brana C, Benham CD, Sundstrom LE (1999) Calpain activation and inhibition in organotypic rat hippocampal slice cultures deprived of oxygen and glucose. Eur J Neurosci 11:2375–2384PubMedGoogle Scholar
  27. 27.
    Bruns J Jr, Hauser WA (2003) The epidemiology of traumatic brain injury: a review. Epilepsia 44(Suppl 10):2–10PubMedGoogle Scholar
  28. 28.
    Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33:95–130PubMedGoogle Scholar
  29. 29.
    Buki A, Farkas O, Doczi T, Povlishock JT (2003) Preinjury administration of the calpain inhibitor MDL-28170 attenuates traumatically induced axonal injury. J Neurotrauma 20:261–268PubMedGoogle Scholar
  30. 30.
    Buki A, Koizumi H, Povlishock JT (1999) Moderate posttraumatic hypothermia decreases early calpain-mediated proteolysis and concomitant cytoskeletal compromise in traumatic axonal injury. Exp Neurol 159:319–328PubMedGoogle Scholar
  31. 31.
    Buki A, Okonkwo DO, Povlishock JT (1999) Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury. J Neurotrauma 16:511–521PubMedGoogle Scholar
  32. 32.
    Buki A, Siman R, Trojanowski JQ, Povlishock JT (1999) The role of calpain-mediated spectrin proteolysis in traumatically induced axonal injury. J Neuropathol Exp Neurol 58:365–375PubMedGoogle Scholar
  33. 33.
    Bulut M, Koksal O, Dogan S, Bolca N, Ozguc H, Korfali E, Ilcol YO, Parklak M (2006) Tau protein as a serum marker of brain damage in mild traumatic brain injury: preliminary results. Adv Ther 23:12–22PubMedGoogle Scholar
  34. 34.
    Cardali S, Maugeri R (2006) Detection of alpha II-spectrin and breakdown products in humans after severe traumatic brain injury. J Neurosurg Sci 50:25–31PubMedGoogle Scholar
  35. 35.
    Carty H, Pierce A (2002) Non-accidental injury: a retrospective analysis of a large cohort. Eur Radiol 12:2919–2925PubMedGoogle Scholar
  36. 36.
    Chen XH, Siman R, Iwata A, Meaney DF, Trojanowski JQ, Smith DH (2004) Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. Am J Pathol 165:357–371PubMedGoogle Scholar
  37. 37.
    da Rocha AB, Schneider RF, de Freitas GR, Andre C, Grivicich I, Zanoni C, Fossa A, Gehrke JT, Pereira JG (2006) Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males. Clin Chem Lab Med 44:1234–1242PubMedGoogle Scholar
  38. 38.
    de Boussard CN, Lundin A, Karlstedt D, Edman G, Bartfai A, Borg J (2005) S100 and cognitive impairment after mild traumatic brain injury. J Rehabil Med 37:53–57PubMedGoogle Scholar
  39. 39.
    De Kruijk Jr, Leffers P, Menheere PP, Meerhoff S, Twijnstra A (2001) S-100B and neuron-specific enolase in serum of mild traumatic brain injury patients. A comparison with health controls. Acta Neurol Scand 103:175–179PubMedGoogle Scholar
  40. 40.
    De Nygren BC, Fredman P, Lundin A, Andersson K, Edman G, Borg J (2004) S100 in mild traumatic brain injury. Brain Inj 18:671–683Google Scholar
  41. 41.
    Dekosky ST, Abrahamson EE, Ciallella JR, Paljug WR, Wisniewski SR, Clark RS, Ikonomovic MD (2007) Association of increased cortical soluble abeta42 levels with diffuse plaques after severe brain injury in humans. Arch Neurol 64:541–544PubMedGoogle Scholar
  42. 42.
    Diakowski W, Sikorski AF (1995) Interaction of brain spectrin (fodrin) with phospholipids. Biochemistry 34:13252–13258PubMedGoogle Scholar
  43. 43.
    Duhaime AC, Partington MD (2002) Overview and clinical presentation of inflicted head injury in infants. Neurosurg Clin N Am 13:149–154PubMedGoogle Scholar
  44. 44.
    Emmerling MR, Morganti-Kossmann MC, Kossmann T, Stahel PF, Watson MD, Evans LM, Mehta PD, Spiegel K, Kuo YM (2000) Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta 42 in human CSF. A possible role for nerve cell injury. Ann N Y Acad Sci 903:118–122PubMedGoogle Scholar
  45. 45.
    Ergun R, Bostanci U, Akdemir G, Beskonakli E, Kaptanoglu E, Gursoy F, Taskin Y (1998) Prognostic value of serum neuron-specific enolase levels after head injury. Neurol Res 20:418–420PubMedGoogle Scholar
  46. 46.
    Fagan AM, Younkin LH, Morris JC, Fryer JD, Cole TG, Younkin SG, Holtzman DM (2000) Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol 48:201–210PubMedGoogle Scholar
  47. 47.
    Fano G, Biocca S, Fulle S, Mariggio MA, Belia S, Calissano P (1995) The S-100: a protein family in search of a function. Prog Neurobiol 46:71–82PubMedGoogle Scholar
  48. 48.
    Farkas O, Polgar B, Szekeres-Bartho J, Doczi T, Povlishock JT, Buki A (2005) Spectrin breakdown products in the cerebrospinal fluid in severe head injury—preliminary observations. Acta Neurochir (Wien) 147:855–861Google Scholar
  49. 49.
    Fasulo L, Ugolini G, Visintin M, Bradbury A, Brancolini C, Verzillo V, Novak M, Cattaneo A (2000) The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis. J Neurochem 75:624–633PubMedGoogle Scholar
  50. 50.
    Fatouros PP, Marmarou A (1999) Use of magnetic resonance imaging for in vivo measurements of water content in human brain: method and normal values. J Neurosurg 90:109–115PubMedGoogle Scholar
  51. 51.
    Field AS, Hasan K, Jellison BJ, Arfanakis K, Alexander AL (2003) Diffusion tensor imaging in an infant with traumatic brain swelling. AJNR Am J Neuroradiol 24:1461–1464PubMedGoogle Scholar
  52. 52.
    Finkelstein E, Corso P, Miller T (2006) The incidence and economic burden of injuries in the United States. Oxford University Press, New YorkGoogle Scholar
  53. 53.
    Finsterer J, Exner M, Rumpold H (2004) Cerebrospinal fluid neuron-specific enolase in non-selected patients. Scand J Clin Lab Invest 64:553–558PubMedGoogle Scholar
  54. 54.
    Fletcher L, Rider CC, Taylor CB (1976) Enolase isoenzymes. III. Chromatographic and immunological characteristics of rat brain enolase. Biochim Biophys Acta 452:245–252PubMedGoogle Scholar
  55. 55.
    Formisano R, Carlesimo GA, Sabbadini M, Loasses A, Penta F, Vinicola V, Caltagirone C (2004) Clinical predictors and neuropsychological outcome in severe traumatic brain injury patients. Acta Neurochir (Wien) 146:457–462Google Scholar
  56. 56.
    Franz G, Beer R, Kampfl A, Engelhardt K, Schmutzhard E, Ulmer H, Deisenhammer F (2003) Amyloid beta 1–42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 60:1457–1461PubMedGoogle Scholar
  57. 57.
    Gabbita SP, Scheff SW, Menard RM, Roberts K, Fugaccia I, Zemlan FP (2005) Cleaved-tau: a biomarker of neuronal damage after traumatic brain injury. J Neurotrauma 22:83–94PubMedGoogle Scholar
  58. 58.
    Ghajar J (2000) Traumatic brain injury. Lancet 356:923–929PubMedGoogle Scholar
  59. 59.
    Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885–890PubMedGoogle Scholar
  60. 60.
    Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3:519–526PubMedGoogle Scholar
  61. 61.
    Goodman SR, Zimmer WE, Clark MB, Zagon IS, Barker JE, Bloom ML (1995) Brain spectrin: of mice and men. Brain Res Bull 36:593–606PubMedGoogle Scholar
  62. 62.
    Hackbarth RM, Rzeszutko KM, Sturm G, Donders J, Kuldanek AS, Sanfilippo DJ (2002) Survival and functional outcome in pediatric traumatic brain injury: a retrospective review and analysis of predictive factors. Crit Care Med 30:1630–1635PubMedGoogle Scholar
  63. 63.
    Hardemark HG, Ericsson N, Kotwica Z, Rundstrom G, Mendel-Hartvig I, Olsson Y, Pahlman S, Persson L (1989) S-100 protein and neuron-specific enolase in CSF after experimental traumatic or focal ischemic brain damage. J Neurosurg 71:727–731PubMedGoogle Scholar
  64. 64.
    Harris AS, Croall DE, Morrow JS (1988) The calmodulin-binding site in alpha-fodrin is near the calcium-dependent protease-I cleavage site. J Biol Chem 263:15754–15761PubMedGoogle Scholar
  65. 65.
    Haviland J, Russell RI (1997) Outcome after severe non-accidental head injury. Arch Dis Child 77:504–507PubMedGoogle Scholar
  66. 66.
    Hayakata T, Shiozaki T, Tasaki O, Ikegawa H, Inoue Y, Toshiyuki F, Hosotubo H, Kieko F, Yamashita T (2004) Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock 22:102–107PubMedGoogle Scholar
  67. 67.
    Herrmann M, Curio N, Jost S, Wunderlich MT, Synowitz H, Wallesch CW (1999) Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury. Restor Neurol Neurosci 14:109–114PubMedGoogle Scholar
  68. 68.
    Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ (2000) Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 31:2670–2677PubMedGoogle Scholar
  69. 69.
    Holmberg B, Johnels B, Blennow K, Rosengren L (2003) Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 18:186–190PubMedGoogle Scholar
  70. 70.
    Horsburgh K, Cole GM, Yang F, Savage MJ, Greenberg BD, Gentleman SM, Graham DI, Nicoll JA (2000) beta-amyloid (Abeta)42(43), abeta42, abeta40 and apoE immunostaining of plaques in fatal head injury. Neuropathol Appl Neurobiol 26:124–132PubMedGoogle Scholar
  71. 71.
    Horsburgh K, Graham DI, Stewart J, Nicoll JA (1999) Influence of apolipoprotein E genotype on neuronal damage and apoE immunoreactivity in human hippocampus following global ischemia. J Neuropathol Exp Neurol 58:227–234PubMedGoogle Scholar
  72. 72.
    Horsburgh K, McCarron MO, White F, Nicoll JA (2000) The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol Aging 21:245–255PubMedGoogle Scholar
  73. 73.
    Huisman TA (2003) Diffusion-weighted imaging: basic concepts and application in cerebral stroke and head trauma. Eur Radiol 13:2283–2297PubMedGoogle Scholar
  74. 74.
    Ingebrigtsen T, Romner B (2002) Biochemical serum markers of traumatic brain injury. J Trauma 52:798–808PubMedGoogle Scholar
  75. 75.
    Ingebrigtsen T, Romner B (2003) Biochemical serum markers for brain damage: a short review with emphasis on clinical utility in mild head injury. Restor Neurol Neurosci 21:171–176PubMedGoogle Scholar
  76. 76.
    Ingebrigtsen T, Romner B, Kongstad P, Langbakk B (1995) Increased serum concentrations of protein S-100 after minor head injury: a biochemical serum marker with prognostic value? J Neurol Neurosurg Psychiatry 59:103–104PubMedGoogle Scholar
  77. 77.
    Ingebrigtsen T, Romner B, Marup-Jensen S, Dons M, Lundqvist C, Bellner J, Alling C, Borgesen SE (2000) The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study. Brain Inj 14:1047–1055PubMedGoogle Scholar
  78. 78.
    Jensen M, Schroder J, Blomberg M, Engvall B, Pantel J, Ida N, Basun H, Wahlund LO, Werle E (1999) Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol 45:504–511PubMedGoogle Scholar
  79. 79.
    Kampfl A, Posmantur R, Nixon R, Grynspan F, Zhao X, Liu SJ, Newcomb JK, Clifton GL, Hayes RL (1996) mu-calpain activation and calpain-mediated cytoskeletal proteolysis following traumatic brain injury. J Neurochem 67:1575–1583PubMedGoogle Scholar
  80. 80.
    Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T (1998) Longitudinal study of cerebrospinal fluid levels of tau, A beta1–40, and A beta1–42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 44:17–26PubMedGoogle Scholar
  81. 81.
    Kavalci C, Pekdemir M, Durukan P, Ilhan N, Yildiz M, Serhatlioglu S, Seckin D (2007) The value of serum tau protein for the diagnosis of intracranial injury in minor head trauma. Am J Emerg Med 25:391–395PubMedGoogle Scholar
  82. 82.
    Kay AD, Petzold A, Kerr M, Keir G, Thompson E, Nicoll JA (2003) Alterations in cerebrospinal fluid apolipoprotein E and amyloid beta-protein after traumatic brain injury. J Neurotrauma 20:943–952PubMedGoogle Scholar
  83. 83.
    Kay AD, Petzold A, Kerr M, Keir G, Thompson EJ, Nicoll JA (2003) Cerebrospinal fluid apolipoprotein E concentration decreases after traumatic brain injury. J Neurotrauma 20:243–250PubMedGoogle Scholar
  84. 84.
    King WJ, MacKay M, Sirnick A (2003) Shaken baby syndrome in Canada: clinical characteristics and outcomes of hospital cases. CMAJ 168:155–159PubMedGoogle Scholar
  85. 85.
    Korfias S, Stranjalis G, Boviatsis E, Psachoulia C, Jullien G, Gregson B, Mendelow AD, Sakas DE (2007) Serum S-100B protein monitoring in patients with severe traumatic brain injury. Intensive Care Med 33:255–260PubMedGoogle Scholar
  86. 86.
    Kosik KS, Finch EA (1987) MAP2 and tau segregate into dendritic and axonal domains after the elaboration of morphologically distinct neurites: an immunocytochemical study of cultured rat cerebrum. J Neurosci 7:3142–3153PubMedGoogle Scholar
  87. 87.
    Laskowitz DT, Sheng H, Bart RD, Joyner KA, Roses AD, Warner DS (1997) Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. J Cereb Blood Flow Metab 17:753–758PubMedGoogle Scholar
  88. 88.
    Laskowitz DT, Thekdi AD, Thekdi SD, Han SK, Myers JK, Pizzo SV, Bennett ER (2001) Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp Neurol 167:74–85PubMedGoogle Scholar
  89. 89.
    Leviton A, Dammann O (2002) Brain damage markers in children. Neurobiological and clinical aspects. Acta Paediatr 91:9–13PubMedGoogle Scholar
  90. 90.
    Li N, Shen JK, Zhao WG, Cai Y, Li YF, Zhan SK (2004) S-100B and neuron specific enolase in outcome prediction of severe head injury. Chin J Traumatol 7:156–158PubMedGoogle Scholar
  91. 91.
    LRJ HPN (1975) The slow component of axonal transport. Identification of major structural polypeptides of the axon and their generality among mammalian neurons. J Cell Biol 66:351–366Google Scholar
  92. 92.
    Lynch JR, Morgan D, Mance J, Matthew WD, Laskowitz DT (2001) Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol 114:107–113PubMedGoogle Scholar
  93. 93.
    Marmarou A, Portella G, Barzo P, Signoretti S, Fatouros P, Beaumont A, Jiang T, Bullock R (2000) Distinguishing between cellular and vasogenic edema in head injured patients with focal lesions using magnetic resonance imaging. Acta Neurochir Suppl 76:349–351PubMedGoogle Scholar
  94. 94.
    McKeating EG, Andrews PJ, Mascia L (1998) Relationship of neuron specific enolase and protein S-100 concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. Acta Neurochir Suppl 71:117–119PubMedGoogle Scholar
  95. 95.
    mer-Wahlin I, Herbst A, Lindoff C, Thorngren-Jerneck K, Marsal K, Alling C (2001) Brain-specific NSE and S-100 proteins in umbilical blood after normal delivery. Clin Chim Acta 304:57–63Google Scholar
  96. 96.
    Missler U, Wiesmann M, Wittmann G, Magerkurth O, Hagenstrom H (1999) Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem 45:138–141PubMedGoogle Scholar
  97. 97.
    Miyata M, Smith JD (1996) Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 14:55–61PubMedGoogle Scholar
  98. 98.
    Mori T, Morimoto K, Hayakawa T, Ushio Y, Mogami H, Sekiguchi K (1978) Radioimmunoassay of astroprotein (an astrocyte-specific cerebroprotein) in cerebrospinal fluid and its clinical significance. Neurol Med Chir (Tokyo) 18:25–31Google Scholar
  99. 99.
    Morris MW, Smith S, Cressman J, Ancheta J (2000) Evaluation of infants with subdural hematoma who lack external evidence of abuse. Pediatrics 105:549–553PubMedGoogle Scholar
  100. 100.
    Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38:643–648PubMedGoogle Scholar
  101. 101.
    Muller K, Townend W, Biasca N, Unden J, Waterloo K, Romner B, Ingebrigtsen T (2007) S100B serum level predicts computed tomography findings after minor head injury. J Trauma 62:1452–1456Google Scholar
  102. 102.
    Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349:1436–1442PubMedGoogle Scholar
  103. 103.
    Naeimi ZS, Weinhofer A, Sarahrudi K, Heinz T, Vecsei V (2006) Predictive value of S-100B protein and neuron specific-enolase as markers of traumatic brain damage in clinical use. Brain Inj 20:463–468PubMedGoogle Scholar
  104. 104.
    Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE (1994) Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264:850–852PubMedGoogle Scholar
  105. 105.
    Netto CB, Conte S, Leite MC, Pires C, Martins TL, Vidal P, Benfato MS, Giugliani R, Goncalves CA (2006) Serum S100B protein is increased in fasting rats. Arch Med Res 37:683–686PubMedGoogle Scholar
  106. 106.
    Newcomb JK, Kampfl A, Posmantur RM, Zhao X, Pike BR, Liu SJ, Clifton GL, Hayes RL (1997) Immunohistochemical study of calpain-mediated breakdown products to alpha-spectrin following controlled cortical impact injury in the rat. J Neurotrauma 14:369–383PubMedGoogle Scholar
  107. 107.
    Nicoll JA, Martin L, Stewart J, Murray LS, Love S, Kennedy PG (2001) Involvement of apolipoprotein E in herpes simplex encephalitis. Neuroreport 12:695–698PubMedGoogle Scholar
  108. 108.
    Nygaard O, Langbakk B, Romner B (1998) Neuron-specific enolase concentrations in serum and cerebrospinal fluid in patients with no previous history of neurological disorder. Scand J Clin Lab Invest 58:183–186PubMedGoogle Scholar
  109. 109.
    Nylen K, Ost M, Csajbok LZ, Nilsson I, Blennow K, Nellgard B, Rosengren L (2006) Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci 240:85–91PubMedGoogle Scholar
  110. 110.
    Olsson A, Csajbok L, Ost M, Hoglund K, Nylen K, Rosengren L, Nellgard B, Blennow K (2004) Marked increase of beta-amyloid(1–42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. J Neurol 251:870–876PubMedGoogle Scholar
  111. 111.
    Ost M, Nylen K, Csajbok L, Ohrfelt AO, Tullberg M, Wikkelso C, Nellgard P, Rosengren L, Blennow K (2006) Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 67:1600–1604PubMedGoogle Scholar
  112. 112.
    Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P, Cepek L, Zerr I, Steinacker P (2000) Decreased beta-amyloid1–42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 54:1099–1102PubMedGoogle Scholar
  113. 113.
    Paterakis K, Karantanas AH, Komnos A, Volikas Z (2000) Outcome of patients with diffuse axonal injury: the significance and prognostic value of MRI in the acute phase. J Trauma 49:1071–1075PubMedGoogle Scholar
  114. 114.
    Pelinka LE, Bahrami S, Szalay L, Umar F, Redl H (2003) Hemorrhagic shock induces an S 100 B increase associated with shock severity. Shock 19:422–426PubMedGoogle Scholar
  115. 115.
    Pelinka LE, Harada N, Szalay L, Jafarmadar M, Redl H, Bahrami S (2004) Release of S100B differs during ischemia and reperfusion of the liver, the gut, and the kidney in rats. Shock 21:72–76PubMedGoogle Scholar
  116. 116.
    Pelinka LE, Hertz H, Mauritz W, Harada N, Jafarmadar M, Albrecht M, Redl H, Bahrami S (2005) Nonspecific increase of systemic neuron-specific enolase after trauma: clinical and experimental findings. Shock 24:119–123PubMedGoogle Scholar
  117. 117.
    Pelinka LE, Jafarmadar M, Redl H, Bahrami S (2004) Neuron-specific-enolase is increased in plasma after hemorrhagic shock and after bilateral femur fracture without traumatic brain injury in the rat. Shock 22:88–91PubMedGoogle Scholar
  118. 118.
    Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H (2004) GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma 21:1553–1561PubMedGoogle Scholar
  119. 119.
    Pelinka LE, Kroepfl A, Schmidhammer R, Krenn M, Buchinger W, Redl H, Raabe A (2004) Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma 57:1006–1012PubMedGoogle Scholar
  120. 120.
    Peterfalvi A, Farkas O, Tamas A, Zsombok A, Reglodi D, Buki A, Lengradi I, Doczi T (2003) Effects of Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) in a rat model of diffuse axonal injury. Ideggyogy Sz 56:1977Google Scholar
  121. 121.
    Pike BR, Flint J, Dutta S, Johnson E, Wang KK, Hayes RL (2001) Accumulation of non-erythroid alpha II-spectrin and calpain-cleaved alpha II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats. J Neurochem 78:1297–1306PubMedGoogle Scholar
  122. 122.
    Pike BR, Zhao X, Newcomb JK, Glenn CC, Anderson DK, Hayes RL (2000) Stretch injury causes calpain and caspase-3 activation and necrotic and apoptotic cell death in septo-hippocampal cell cultures. J Neurotrauma 17:283–298PubMedGoogle Scholar
  123. 123.
    Pike BR, Zhao X, Newcomb JK, Posmantur RM, Wang KK, Hayes RL (1998) Regional calpain and caspase-3 proteolysis of alpha-spectrin after traumatic brain injury. Neuroreport 9:2437–2442PubMedGoogle Scholar
  124. 124.
    Pineda JA, Lewis SB, Valadka AB, Papa L, Hannay HJ, Heaton SC, Demery JA, Liu MC, Aikman JM (2007) Clinical significance of alpha II-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma 24:354–366PubMedGoogle Scholar
  125. 125.
    Povlishock JT, Christman CW (1995) The pathobiology of traumatically induced axonal injury in animals and humans: a review of current thoughts. J Neurotrauma 12:555–564PubMedGoogle Scholar
  126. 126.
    Povlishock JT, Pettus EH (1996) Traumatically induced axonal damage: evidence for enduring changes in axolemmal permeability with associated cytoskeletal change. Acta Neurochir Suppl 66:81–86PubMedGoogle Scholar
  127. 127.
    Raabe A, Grolms C, Sorge O, Zimmermann M, Seifert V (1999) Serum S-100B protein in severe head injury. Neurosurgery 45:477–483PubMedGoogle Scholar
  128. 128.
    Raabe A, Menon DK, Gupta S, Czosnyka M, Pickard JD (1998) Jugular venous and arterial concentrations of serum S-100B protein in patients with severe head injury: a pilot study. J Neurol Neurosurg Psychiatry 65:930–932PubMedGoogle Scholar
  129. 129.
    Raby CA, Morganti-Kossmann MC, Kossmann T, Stahel PF, Watson MD, Evans LM, Mehta PD, Spiegel K, Kuo YM (1998) Traumatic brain injury increases beta-amyloid peptide 1–42 in cerebrospinal fluid. J Neurochem 71:2505–2509PubMedCrossRefGoogle Scholar
  130. 130.
    Rifai N, Christenson RH, Gelman BB, Silverman LM (1987) Changes in cerebrospinal fluid IgG and apolipoprotein E indices in patients with multiple sclerosis during demyelination and remyelination. Clin Chem 33:1155–1157PubMedGoogle Scholar
  131. 131.
    Ringger NC, O'Steen BE, Brabham JG, Silver X, Pineda J, Wang KK, Hayes RL, Papa L (2004) A novel marker for traumatic brain injury: CSF alpha II-spectrin breakdown product levels. J Neurotrauma 21:1443–1456PubMedGoogle Scholar
  132. 132.
    Roberts GW, Gentleman SM, Lynch A, Graham DI (1991) beta A4 amyloid protein deposition in brain after head trauma. Lancet 338:1422–1423PubMedGoogle Scholar
  133. 133.
    Romner B, Ingebrigtsen T, Kongstad P, Borgesen SE (2000) Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. J Neurotrauma 17:641–647PubMedGoogle Scholar
  134. 134.
    Ross SA, Cunningham RT, Johnston CF, Rowlands BJ (1996) Neuron-specific enolase as an aid to outcome prediction in head injury. Br J Neurosurg 10:471–476PubMedGoogle Scholar
  135. 135.
    Rothoerl RD, Brawanski A, Woertgen C (2000) S-100B protein serum levels after controlled cortical impact injury in the rat. Acta Neurochir (Wien) 142:199–203Google Scholar
  136. 136.
    Rothoerl RD, Woertgen C, Holzschuh M, Metz C, Brawanski A (1998) S-100 serum levels after minor and major head injury. J Trauma 45:765–767PubMedGoogle Scholar
  137. 137.
    Saatman KE, Bozyczko-Coyne D, Marcy V, Siman R, McIntosh TK (1996) Prolonged calpain-mediated spectrin breakdown occurs regionally following experimental brain injury in the rat. J Neuropathol Exp Neurol 55:850–860PubMedGoogle Scholar
  138. 138.
    Sandor J, Szucs M, Kiss I, Ember I, Csepregi G, Futo J, Vimlati L, Pal J, Buki A (2003) Risk factors for fatal outcome in subdural hemorrhage. Ideggyogy Sz 56:386–395PubMedGoogle Scholar
  139. 139.
    Savola O, Hillbom M (2003) Early predictors of post-concussion symptoms in patients with mild head injury. Eur J Neurol 10:175–181PubMedGoogle Scholar
  140. 140.
    Sawauchi S, Taya K, Murakami S, Ishi T, Ohtsuka T, Kato N, Kaku S, Tanaka T, Morooka S (2005) Serum S-100B protein and neuron-specific enolase after traumatic brain injury. No Shinkei Geka 33:1073–1080PubMedGoogle Scholar
  141. 141.
    Schaan M, Jaksche H, Boszczyk B (2002) Predictors of outcome in head injury: proposal of a new scaling system. J Trauma 52:667–674PubMedGoogle Scholar
  142. 142.
    Schauwecker PE, Cogen JP, Jiang T, Cheng HW, Collier TJ, McNeill TH (1998) Differential regulation of astrocytic mRNAs in the rat striatum after lesions of the cortex or substantia nigra. Exp Neurol 149:87–96PubMedGoogle Scholar
  143. 143.
    Schmechel D, Marangos PJ, Brightman M (1978) Neuron-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature 276:834–836PubMedGoogle Scholar
  144. 144.
    Schofield PW, Tang M, Marder K, Bell K, Dooneief G, Chun M, Sano M, Stern Y, Mayeux R (1997) Alzheimer's disease after remote head injury: an incidence study. J Neurol Neurosurg Psychiatry 62:119–124PubMedGoogle Scholar
  145. 145.
    Schuhmann MU, Stiller D, Skardelly M, Bernarding J, Klinge PM, Samii A, Samii M, Brinker T (2003) Metabolic changes in the vicinity of brain contusions: a proton magnetic resonance spectroscopy and histology study. J Neurotrauma 20:725–743PubMedGoogle Scholar
  146. 146.
    Sergeant N, Delacourte A, Buee L (2005) Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta 1739:179–197PubMedGoogle Scholar
  147. 147.
    Shaw GJ, Jauch EC, Zemlan FP (2002) Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury. Ann Emerg Med 39:254–257PubMedGoogle Scholar
  148. 148.
    Shore PM, Berger RP, Varma S, Janesko KL, Wisniewski SR, Clark RS, Adelson PD, Thomas NJ, Lai YC (2007) Cerebrospinal fluid biomarkers versus Glasgow coma scale and Glasgow outcome scale in pediatric traumatic brain injury: the role of young age and inflicted injury. J Neurotrauma 24:75–86PubMedGoogle Scholar
  149. 149.
    Sjogren M, Davidsson P, Wallin A, Granerus AK, Grundstrom E, Askmark H, Vanmechelen E, Blennow K (2002) Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord 13:112–118PubMedGoogle Scholar
  150. 150.
    Skogseid IM, Nordby HK, Urdal P, Paus E, Lilleaas F (1992) Increased serum creatine kinase BB and neuron specific enolase following head injury indicates brain damage. Acta Neurochir (Wien) 115:106–111Google Scholar
  151. 151.
    Spinella PC, Dominguez T, Drott HR, Huh J, McCormick L, Rajendra A, Argon J, McIntosh T, Helfaer M (2003) S-100beta protein-serum levels in healthy children and its association with outcome in pediatric traumatic brain injury. Crit Care Med 31:939–945PubMedGoogle Scholar
  152. 152.
    Stalnacke BM, Elgh E, Sojka P (2005) One-year follow-up of mild traumatic brain injury: cognition, disability and life satisfaction of patients seeking consultation. J Rehabil Med 39:405–411Google Scholar
  153. 153.
    Stapert S, de KJ, Houx P, Menheere P, Twijnstra A, Jolles J (2005) S-100B concentration is not related to neurocognitive performance in the first month after mild traumatic brain injury. Eur Neurol 53:22–26PubMedGoogle Scholar
  154. 154.
    Stone JR, Okonkwo DO, Singleton RH, Mutlu LK, Helm GA, Povlishock JT (2002) Caspase-3-mediated cleavage of amyloid precursor protein and formation of amyloid Beta peptide in traumatic axonal injury. J Neurotrauma 19:601–614PubMedGoogle Scholar
  155. 155.
    Stranjalis G, Korfias S, Papapetrou C, Kouyialis A, Boviatsis E, Psachoulia C, Sakas DE (2004) Elevated serum S-100B protein as a predictor of failure to short-term return to work or activities after mild head injury. J Neurotrauma 21:1070–1075PubMedGoogle Scholar
  156. 156.
    Tagliaferri F, Compagnone C, Korsic M, Servadei F, Kraus J (2006) A systematic review of brain injury epidemiology in Europe. Acta Neurochir (Wien) 148:255–268Google Scholar
  157. 157.
    Takanashi Y, Shinonaga M (2001) Magnetic resonance imaging for surgical consideration of acute head injury. J Clin Neurosci 8:240–244PubMedGoogle Scholar
  158. 158.
    Tamaoka A, Kondo T, Odaka A, Sahara N, Sawamura N, Ozawa K, Suzuki N, Shoji S, Mori H (1994) Biochemical evidence for the long-tail form (A beta 1–42/43) of amyloid beta protein as a seed molecule in cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun 205:834–842PubMedGoogle Scholar
  159. 159.
    Teasdale GM, Nicoll JA, Murray G, Fiddes M (1997) Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 350:1069–1071PubMedGoogle Scholar
  160. 160.
    Tolias CM, Bullock MR (2004) Critical appraisal of neuroprotection trials in head injury: what have we learned? NeuroRx 1:71–79PubMedGoogle Scholar
  161. 161.
    Townend W, Ingebrigtsen T (2006) Head injury outcome prediction: a role for protein S-100B? Injury 37:1098–1108PubMedGoogle Scholar
  162. 162.
    Ucar T, Baykal A, Akyuz M, Dosemeci L, Toptas B (2004) Comparison of serum and cerebrospinal fluid protein S-100b levels after severe head injury and their prognostic importance. J Trauma 57:95–98PubMedGoogle Scholar
  163. 163.
    Unden J, Astrand R, Waterloo K, Ingebrigtsen T, Bellner J, Reinstrup P, Andsberg G, Romner B (2007) Clinical significance of serum S100B levels in neurointensive care. Neurocrit Care 6:94–99Google Scholar
  164. 164.
    Vajtr D, Prusa R, Kukacka J, Houst'ava L, Samal F, Pelichovska M, Strejc P, Toupalik P (2007) Evaluation of relevance in concussion and damage of health by monitoring of neuron specific enolase and S-100b protein. Soud Lek 52:43–46PubMedGoogle Scholar
  165. 165.
    Van Nostrand WE, Wagner SL, Shankle WR, Farrow JS, Dick M, Rozemuller JM, Kuiper MA, Wolters EC, Zimmerman J (1992) Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci U S A 89:2551–2555PubMedGoogle Scholar
  166. 166.
    Vos PE, Lamers KJ, Hendriks JC, van HM, Beems T, Zimmerman C, van GW, de RH, Biert J, Verbeek MM (2004) Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 62:1303–1310PubMedGoogle Scholar
  167. 167.
    Wang KK, Posmantur R, Nath R, McGinnis K, Whitton M, Talanian RV, Glantz SB, Morrow JS (1998) Simultaneous degradation of alpha II- and beta II-spectrin by caspase 3 (CPP32) in apoptotic cells. J Biol Chem 273:22490–22497PubMedGoogle Scholar
  168. 168.
    Whitaker-Azmitia PM, Wingate M, Borella A, Gerlai R, Roder J, Azmitia EC (1997) Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer's disease and Down's syndrome. Brain Res 776:51–60PubMedGoogle Scholar
  169. 169.
    White F, Nicoll JA, Horsburgh K (2001) Alterations in ApoE and ApoJ in relation to degeneration and regeneration in a mouse model of entorhinal cortex lesion. Exp Neurol 169:307–318PubMedGoogle Scholar
  170. 170.
    Wiesmann M, Missler U, Gottmann D, Gehring S (1998) Plasma S-100b protein concentration in healthy adults is age- and sex-independent. Clin Chem 44:1056–1058PubMedGoogle Scholar
  171. 171.
    Woertgen C, Rothoerl RD, Brawanski A (2001) Neuron-specific enolase serum levels after controlled cortical impact injury in the rat. J Neurotrauma 18:569–573PubMedGoogle Scholar
  172. 172.
    Woertgen C, Rothoerl RD, Holzschuh M, Metz C, Brawanski A (1997) Comparison of serial S-100 and NSE serum measurements after severe head injury. Acta Neurochir (Wien) 139:1161–1164Google Scholar
  173. 173.
    Woertgen C, Rothoerl RD, Metz C, Brawanski A (1999) Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. J Trauma 47:1126–1130PubMedGoogle Scholar
  174. 174.
    Woertgen C, Rothoerl RD, Wiesmann M, Missler U, Brawanski A (2002) Glial and neuronal serum markers after controlled cortical impact injury in the rat. Acta Neurochir Suppl 81:205–207PubMedGoogle Scholar
  175. 175.
    Yakovlev AG, Faden AI (2004) Mechanisms of neural cell death: implications for development of neuroprotective treatment strategies. NeuroRx 1:5–16PubMedGoogle Scholar
  176. 176.
    Yamazaki Y, Yada K, Morii S, Kitahara T, Ohwada T (1995) Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. Surg Neurol 43:267–270PubMedGoogle Scholar
  177. 177.
    Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale SG, Zuccarello M (2002) C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. Brain Res 947:131–139PubMedGoogle Scholar
  178. 178.
    Zemlan FP, Rosenberg WS, Luebbe PA, Campbell TA, Dean GE, Weiner NE, Cohen JA, Rudick RA, Woo D (1999) Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem 72:741–750PubMedGoogle Scholar
  179. 179.
    Zimmer DB, Cornwall EH, Landar A, Song W (1995) The S100 protein family: history, function, and expression. Brain Res Bull 37:417–429PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Erzsébet Kövesdi
    • 1
  • János Lückl
    • 2
  • Péter Bukovics
    • 1
    • 3
  • Orsolya Farkas
    • 1
  • József Pál
    • 1
  • Endre Czeiter
    • 1
  • Dóra Szellár
    • 1
  • Tamás Dóczi
    • 1
  • Sámuel Komoly
    • 4
  • András Büki
    • 1
  1. 1.Department of NeurosurgeryUniversity of PécsPécsHungary
  2. 2.Department of NeurologyUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.Neurobiology Research Group of the Hungarian Academy of SciencesPécsHungary
  4. 4.Department of NeurologyUniversity of PécsPécsHungary

Personalised recommendations